Literature DB >> 24388020

Epidemiological profile of Marfan syndrome in a general population: a national database study.

Hsin-Hui Chiu1, Mei-Hwan Wu2, Hui-Chi Chen3, Feng-Yu Kao4, San-Kuei Huang4.   

Abstract

OBJECTIVE: To explore the current epidemiological profile of Marfan syndrome in a general population. PATIENTS AND METHODS: Patients who had received a diagnosis of Marfan syndrome were identified from the Taiwan National Health Insurance database records from January 1, 2000, through December 31, 2012 (average population size, 22,765,535). Cardiovascular events and interventions were identified by using the respective International Classification of Diseases codes.
RESULTS: We identified 2329 patients (58% men) with Marfan syndrome. The overall prevalence was 10.2 (95% CI, 9.8-10.7) per 100,000 individuals, with peaks at the age of 15 to 19, 10 to 14, and 20 to 24 years. The minimal birth incidence of 23.3 (95% CI, 21.7-23.3) per 100,000 individuals was estimated in those aged 20 to 29 years. The average annual mortality was 0.23% (69 deaths), mostly owing to cardiac causes (including dissection and sudden death in 40 patients, 58%). Aortic dissection occurred in 226 patients (10%; 61% men) at a mean age of 36.6±10.7 years. The probability of freedom from dissection was 99%, 80%, and 66% at the age of 20, 40, and 50 years, respectively. Of the 69 deaths and 226 dissections during the follow-up period, more than half of the cases occurred before the age of 40 years. Cardiovascular intervention was performed in 360 patients, with early mortality being higher in the emergent operation group (8%) than in the elective group (0%).
CONCLUSION: From this national cohort study, the minimal birth incidence was 23.3 per 100,000 individuals, that is, possibly 1 patient with Marfan syndrome per 4286 people. Despite medical advances, aortic dissection still occurs in about one-tenth of the patients and carries a high mortality risk. Early diagnosis and timely medical interventions are warranted.
Copyright © 2014 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ACEI; NHI; National Health Insurance; angiotensin-converting enzyme inhibitor

Mesh:

Year:  2014        PMID: 24388020     DOI: 10.1016/j.mayocp.2013.08.022

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  25 in total

1.  Marfan syndrome with pneumothorax: case report and review of literatures.

Authors:  Weiming Hao; Yong Fang; Hao Lai; Yaxing Shen; Hao Wang; Miao Lin; Lijie Tan
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

Review 2.  Cardiovascular Management of Adults with Marfan Syndrome.

Authors:  Yukiko Isekame; Sabiha Gati; Jose Antonio Aragon-Martin; Rachel Bastiaenen; Sreenivasa Rao Kondapally Seshasai; Anne Child
Journal:  Eur Cardiol       Date:  2016-12

Review 3.  Marfan syndrome.

Authors:  Dianna M Milewicz; Alan C Braverman; Julie De Backer; Shaine A Morris; Catherine Boileau; Irene H Maumenee; Guillaume Jondeau; Arturo Evangelista; Reed E Pyeritz
Journal:  Nat Rev Dis Primers       Date:  2021-09-02       Impact factor: 65.038

Review 4.  Perspectives on the revised Ghent criteria for the diagnosis of Marfan syndrome.

Authors:  Yskert von Kodolitsch; Julie De Backer; Helke Schüler; Peter Bannas; Cyrus Behzadi; Alexander M Bernhardt; Mathias Hillebrand; Bettina Fuisting; Sara Sheikhzadeh; Meike Rybczynski; Tilo Kölbel; Klaus Püschel; Stefan Blankenberg; Peter N Robinson
Journal:  Appl Clin Genet       Date:  2015-06-16

5.  Design and rationale of a prospective, collaborative meta-analysis of all randomized controlled trials of angiotensin receptor antagonists in Marfan syndrome, based on individual patient data: A report from the Marfan Treatment Trialists' Collaboration.

Authors:  Alex Pitcher; Jonathan Emberson; Ronald V Lacro; Lynn A Sleeper; Mario Stylianou; Lynn Mahony; Gail D Pearson; Maarten Groenink; Barbara J Mulder; Aeilko H Zwinderman; Julie De Backer; Anne M De Paepe; Eloisa Arbustini; Guliz Erdem; Xu Yu Jin; Marcus D Flather; Michael J Mullen; Anne H Child; Alberto Forteza; Arturo Evangelista; Hsin-Hui Chiu; Mei-Hwan Wu; George Sandor; Ami B Bhatt; Mark A Creager; Richard B Devereux; Bart Loeys; J Colin Forfar; Stefan Neubauer; Hugh Watkins; Catherine Boileau; Guillaume Jondeau; Harry C Dietz; Colin Baigent
Journal:  Am Heart J       Date:  2015-02-12       Impact factor: 4.749

6.  Prevalence, incidence, and age at diagnosis in Marfan Syndrome.

Authors:  Kristian A Groth; Hanne Hove; Kasper Kyhl; Lars Folkestad; Mette Gaustadnes; Niels Vejlstrup; Kirstine Stochholm; John R Østergaard; Niels H Andersen; Claus H Gravholt
Journal:  Orphanet J Rare Dis       Date:  2015-12-02       Impact factor: 4.123

7.  Structural equation modeling of the quality of life for patients with marfan syndrome.

Authors:  Ju Ryoung Moon; Yong Ae Cho; June Huh; I-Seok Kang; Duk-Kyung Kim
Journal:  Health Qual Life Outcomes       Date:  2016-06-02       Impact factor: 3.186

8.  Adolescent BMI at Northern Israel: From Trends, to Associated Variables and Comorbidities, and to Medical Signatures.

Authors:  Yossy Machluf; Daniel Fink; Rivka Farkash; Ron Rotkopf; Avinoam Pirogovsky; Orna Tal; Tamar Shohat; Giora Weisz; Erez Ringler; David Dagan; Yoram Chaiter
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

9.  Personalised External Aortic Root Support (PEARS) Compared with Alternatives for People with Life-Threatening Genetically Determined Aneurysms of the Aortic Root.

Authors:  Tom Treasure; John Pepper
Journal:  Diseases       Date:  2015-01-15

10.  Detection of Pathological Changes in the Aorta during Thoracic Aortic Aneurysm Progression on Molecular Level.

Authors:  Miroslava Rabajdová; Peter Urban; Ivana Špaková; Artemiou Panagiotis; Michaela Ferenčáková; Dušan Rybár; Nikita Bobrov; František Sabol; Mária Mareková
Journal:  Dis Markers       Date:  2017-10-12       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.